FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy

ALSO NOTED: Takeda, Galaxy Biotech ink licensing deal; Protalex raises $15.2M in private placement; and much more...

Tools

> Antigenics has expanded its licensing and supply deals for QS-21 Stimulon adjuvant with a vaccine division of GlaxoSmithKline. Release

> New Hope, PA-based Protalex has raised approximately $15.2 million in a private placement of 6.1 million shares of common stock. Release

> BioSante Pharmaceuticals announced a $7.6 million private placement. Release

> Takeda has signed an agreement to develop, manufacture and sell Galaxy Biotech's monoclonal antibody and will earn additional payments if the drug reaches certain milestones. Report

> AnorMED has completed enrollment in two Phase II trials for Mozobil for stem cell transplant. Release

And Finally... Florida's Supreme Court has ruled that pharmacists are responsible if a patient is harmed by a prescription drug combination. Report


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceBiotech Email Newsletter:

More stories about Anormed   GlaxoSmithKline   Phase II   monoclonal antibody   private placement   milestones   Takeda   Biotech Stock   adjuvant